Based on the statements made by the President of the company during the bio-tech conference conference in San Francisco, the FDA advised the company that they could use the data base on the one million patients already on Byetta, to meet the criteria… More
People are focusing on Pancreatitis.
The real issue is competition. Byetta is an adjunt therapy in uncontrolled patients. Now we have Januvia, who pretty much does the same thing, is oral and cheaper than Byetta. People do not like needles,… More